Source: GlobalNewswire

Press Release: Biosplice Therapeutics : Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis

Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.

Read full article »
Biosplice Therapeutics's Competitors | Biosplice Therapeutics's News | Biosplice Therapeutics's Financials
Stay up-to-date with the latest news on Biosplice Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Cevdet Samikoglu's photo - CEO of Biosplice Therapeutics

CEO

Cevdet Samikoglu

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Biosplice Therapeutics